Quantum Phase Slips in one-dimensional Josephson Junction Chains

We have studied quantum phase-slip (QPS) phenomena in long one-dimensional Josephson junction series arrays with tunable Josephson coupling. These chains were fabricated with as many as 2888 junctions, where one sample had a tunable weak link in the middle. Measurements were made of the zero-bias resistance, $R_0$, as well as current-voltage characteristics (IVC). The finite $R_0$ is explained by QPS and shows an exponential dependence on $\sqrt{E_J/E_C}$ with a distinct change in the exponent at $R_0=R_Q=h/4e^2$. When $R_0 > R_Q$ the IVC clearly shows a remnant of the Coulomb blockade, which evolves to a zero-current state with a sharp critical voltage as $E_J$ is tuned to a smaller value. The zero-current state below the critical voltage is due to coherent QPS and we show that these are enhanced at the central weak link. Above the critical voltage a negative differential resistance is observed which nearly restores the zero-current state

EPIDEMIOLOGICAL CHARACTERISTICS OF VIRAL HEPATITIS IN PATIENTS WITH RHEUMATIC DISEASES - IMPLICATIONS FROM TREASURE DATABASE

EULAR European Congress of Rheumatology (EULAR) -- JUN 01-04, 2022 -- Copenhagen, DENMARK[Abstract Not Available]European Alliance Assoc Rheumato

PARADOXICAL REACTIONS, ESPECIALLY PSORIASIS IN RHEUMATOLOGY PATIENTS RECEIVING BIOLOGIC THERAPY FROM THE TREASURE DATABASE: A 5-YEAR FOLLOW-UP STUDY

EULAR European Congress of Rheumatology (EULAR) -- JUN 01-04, 2022 -- Copenhagen, DENMARK[Abstract Not Available]European Alliance Assoc Rheumato

BIOLOGIC DRUG PREFERENCES OF TURKISH RHEUMATOLOGISTS IN SPONDILOARTROPATHY PATIENTS WITH ADVANCED CHRONIC RENAL DISEASE

[Abstract Not Available

THE DIFFERENCES BETWEEN THE FIRST PREFERRED BIOLOGICAL DMARD AND THE DRUG SURVIVAL IN GERIATRIC AND YOUNGER ADULT POPULATION WITH RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS: TREASURE REAL-LIFE DATA

EULAR European Congress of Rheumatology (EULAR) -- JUN 01-04, 2022 -- Copenhagen, DENMARK[Abstract Not Available]European Alliance Assoc Rheumato

Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data

Objective To determine the real-life efficacy, safety, and drug-retention rates of leflunomide (LEF) or methotrexate (MTX) as a synthetic DMARD used in combination with biological DMARDs for rheumatoid arthritis (RA). Methods The TReasure database is a web-based, prospective, observational cohort of RA and spondyloarthritis patients from 17 centres in different regions of Turkey and data entry was enabled since December 2017. Until May 2019,2556 RA patients on biologic treatment were recorded. Demographic and RA-related data of 1526 patient either received LEF or MTX were compared, efficacy of both drugs compared by RA-disease activity composite indices. Reasons fordrug discontinuation also recorded. Drug retention rates were compared with Kaplan-Meier curves (log-rank test). Results Of 2556 RA patients 1526 (59.7%) were receiving concomitant LEE (n=646, 42 3%; median follow up 35 months) or concomitant MTX (n=880, 573%; median follow-up 32 months) at the time of initiation to their first bDMARDs. The LEE group were older and had longer disease duration, proportion of females and seropositive patients was higher in this group. In the LEE group, non-anti-TNF agents were used in higher rate. Remission rates, changes in composite indices and rate of comorbidities and adverse events were similar in both groups. The retention rate of LEE + non-anti-TNF b/tsDMARDs was higher compared to MTX + anti-TNF bDMARDs (p=0.002, log-rank). Rates of adverse events were similar in both groups. Conclusion LEE in combination with either anti TNF or non anti DIF drugs appears as an effective and safe therapeutic option at least as MIX.Hacettepe Rheumatology Societythis study was funding by Hacettepe Rheumatology Society. Competing interests: see page 858